Â鶹´«Ã½

    Advertisement
    BioSpectrum Asia23:35Novo Nordisk China Pharma
    Pharmaceutical Technology12:26Novo Nordisk Obesity Pharma
    Benzinga09:25Novo Nordisk Obesity Pharma
    Proactive Investors (US)08:29Novo Nordisk Ozempic US Banking
    Yahoo! UK & Ireland13:35Novo Nordisk Eli Lilly Pharma
    Yahoo! US04:51Novo Nordisk Eli Lilly Pharma
    Finance in Bold12:55Eli Lilly Novo Nordisk NYSE
    Proactive Investors (US)09:32Eli Lilly Novo Nordisk NYSE
    The Hindu Business Line12:23Ozempic Novo Nordisk Eli Lilly
    Benzinga14:11Novo Nordisk Pharma
    In the last half-hour
    RTE02:17
    Yesterday
    The Hindu Business Line12:23 1-Apr-25
    In the last 7 days
    Quartz13:54 31-Mar-25
    Benzinga09:36 31-Mar-25
    Scrip Pharma Intelligence23:05 30-Mar-25
    Seeking Alpha21:17 29-Mar-25
    BioWorld17:33 28-Mar-25
    Finance in Bold12:55 28-Mar-25
    TipRanks12:37 28-Mar-25
    Pharmaceutical Technology12:26 28-Mar-25
    Scrip Pharma Intelligence12:24 28-Mar-25
    FiercePharma09:32 28-Mar-25
    Benzinga09:25 28-Mar-25
    Proactive Investors (US)08:29 28-Mar-25
    ENDPOINTS07:38 28-Mar-25
    Quartz05:08 28-Mar-25
    The Motley Fool18:40 27-Mar-25
    Quartz17:06 27-Mar-25
    Yahoo! UK & Ireland13:35 27-Mar-25
    GlobeNewswire (Press Release)11:23 27-Mar-25
    Law36022:00 26-Mar-25
    Benzinga14:11 26-Mar-25
    Forbes08:06 26-Mar-25
    In the last month
    Pharmaceutical Technology13:27 25-Mar-25
    Zacks12:33 25-Mar-25
    PMLiVE08:30 25-Mar-25
    BioSpectrum Asia23:35 24-Mar-25
    BioWorld17:41 24-Mar-25
    The Economic Times15:45 24-Mar-25
    GlobeNewswire (Press Release)13:20 24-Mar-25
    The Motley Fool12:50 24-Mar-25
    Quartz12:45 24-Mar-25
    Scrip Pharma Intelligence12:38 24-Mar-25
    Benzinga10:52 24-Mar-25
    London South East10:18 24-Mar-25
    Proactive Investors (US)09:32 24-Mar-25
    CyberNews09:31 24-Mar-25
    KELO TV09:12 24-Mar-25
    pharmaphorum08:56 24-Mar-25
    Irish Examiner08:27 24-Mar-25
    ENDPOINTS07:44 24-Mar-25
    KELO TV07:20 24-Mar-25
    GlobeNewswire (Press Release)06:03 24-Mar-25
    Yahoo! UK & Ireland05:52 24-Mar-25
    Yahoo! US04:51 24-Mar-25
    KELO TV13:31 21-Mar-25
    EasternEye13:07 21-Mar-25
    Bloomberg Law10:29 21-Mar-25
    Indian Express05:39 21-Mar-25
    The Irish Times01:09 21-Mar-25
    The Telegraph, Calcutta07:16 20-Mar-25
    The Korea Times07:06 20-Mar-25
    PMLiVE08:21 19-Mar-25
    The Motley Fool16:50 18-Mar-25
    TCTMD15:49 18-Mar-25
    Daily Sabah07:04 18-Mar-25
    RTE07:01 18-Mar-25
    Yahoo! US02:13 18-Mar-25
    PR Newswire (Press Release)08:02 17-Mar-25
    GlobeNewswire (Press Release)05:41 17-Mar-25
    Bangkok Post04:47 17-Mar-25
    Korea Biomedical Review22:27 16-Mar-25
    Zacks11:03 14-Mar-25
    Scrip Pharma Intelligence13:33 13-Mar-25
    Quartz12:57 13-Mar-25
    Yahoo! US10:06 13-Mar-25
    Korea Biomedical Review02:56 13-Mar-25
    Yahoo! US15:14 12-Mar-25
    Chemistry World Magazine12:09 12-Mar-25
    Yahoo! US12:07 12-Mar-25
    Bloomberg Law05:47 12-Mar-25
    Scrip Pharma Intelligence11:10 11-Mar-25
    BioPharma Dive09:26 11-Mar-25
    PR Newswire (Press Release)08:09 11-Mar-25
    Entrepreneur Magazine21:01 10-Mar-25
    KELO TV16:37 10-Mar-25
    TipRanks15:46 10-Mar-25
    GlobeNewswire (Press Release)14:21 10-Mar-25
    Clinical Trials Arena11:51 10-Mar-25
    ENDPOINTS11:24 10-Mar-25
    Fox News11:13 10-Mar-25
    Proactive Investors (US)10:50 10-Mar-25
    Yahoo! UK & Ireland10:19 10-Mar-25
    Yahoo! US10:15 10-Mar-25
    Yahoo! UK & Ireland09:59 10-Mar-25
    FierceBiotech09:31 10-Mar-25
    pharmaphorum08:21 10-Mar-25
    TipRanks08:18 10-Mar-25
    Invezz08:10 10-Mar-25
    KELO TV07:58 10-Mar-25
    ENDPOINTS07:30 10-Mar-25
    GlobeNewswire (Press Release)06:29 10-Mar-25
    Bloomberg Law06:20 10-Mar-25
    The Irish Times09:11 9-Mar-25
    Money Morning10:36 7-Mar-25
    Quartz05:11 7-Mar-25
    TipRanks14:16 6-Mar-25
    Semafor12:40 6-Mar-25
    Gulf News09:49 6-Mar-25
    FiercePharma08:53 6-Mar-25
    The Irish Times08:45 6-Mar-25
    Zacks08:05 6-Mar-25
    Power Corridor06:34 6-Mar-25
    pharmaphorum05:02 6-Mar-25
    euronews01:32 6-Mar-25
    TipRanks01:22 6-Mar-25
    Scrip Pharma Intelligence18:36 5-Mar-25
    Yahoo! US15:05 5-Mar-25
    PBS Online13:21 5-Mar-25
    Fox News13:05 5-Mar-25
    Bloomberg Law13:04 5-Mar-25
    MailOnline12:04 5-Mar-25
    ENDPOINTS11:55 5-Mar-25
    Yahoo! UK & Ireland11:05 5-Mar-25
    Yahoo! US11:04 5-Mar-25
    view more headlines
    2 Apr 02:17

    About our Amycretin news

    Latest news on Amycretin: Novo Nordisk's promising obesity pill. Trial results, weight loss data, availability updates, and expert insights.

    Amycretin, an experimental once-daily pill developed by Danish pharmaceutical giant Novo Nordisk, has shown remarkable promise in early-stage trials. This innovative treatment combines the effects of Novo's successful injectable medications, such as Wegovy and Ozempic, into a single oral medication, potentially offering a more convenient option for those struggling with obesity.

    In a 12-week Phase 1 clinical trial, patients taking Amycretin achieved an impressive average weight loss of 13%, surpassing the results seen with competitor Eli Lilly's experimental pill. These findings have generated significant excitement within the medical community and among individuals eager for new, effective obesity treatments. As Novo Nordisk moves forward with further clinical trials, our feed will keep you informed about the latest developments, including efficacy data, safety profiles, and regulatory milestones.

    The potential impact of Amycretin extends beyond individual health outcomes. With obesity rates rising globally and the associated healthcare costs soaring, an effective and accessible treatment could have far-reaching implications for public health systems and economies. Our feed will explore these broader societal and economic aspects of Amycretin, as well as its potential to transform the lives of millions of people grappling with obesity and its related comorbidities, such as diabetes, heart disease, and certain cancers.

    As Amycretin progresses through the clinical trial process, our feed will also cover any challenges or controversies that may arise, such as concerns over long-term safety, access and affordability issues, and the ethical dimensions of weight loss medications. We will provide a balanced and nuanced perspective, featuring insights from medical experts, patient advocates, and industry leaders.

    Stay tuned for the latest news on Amycretin's development, as well as updates on Novo Nordisk's other groundbreaking obesity medications, such as the injectable treatments Wegovy and Ozempic. As the race to develop effective and safe weight loss solutions intensifies, with competitors like Eli Lilly's Zepbound entering the fray, our feed will be your go-to source for comprehensive coverage and expert analysis of this dynamic and transformative field.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.